Tivozanib
| Code | Size | Price |
|---|
| SYN-1013-M100 | 100 mg | Enquire |
Quantity:
| SYN-1013-M001 | 1 mg | £104.00 |
Quantity:
| SYN-1013-M005 | 5 mg | £162.00 |
Quantity:
| SYN-1013-M010 | 10 mg | £227.00 |
Quantity:
| SYN-1013-M050 | 50 mg | £719.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
AV-951
Appearance:
Solid.
CAS:
475108-18-0
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
InChiKey:
SPMVMDHWKHCIDT-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 475108-18-0. Formula: C22H19ClN4O5. MW: 454.9. Tivozanib is a potent inhibitor of VEGFR-1, 2 & 3 (IC(50) 0.21, 0.16 and 0.24nM respectively).
Molecular Formula:
C22H19ClN4O5
Molecular Weight:
454.9
Package Type:
Plastic Vial
Product Description:
Tivozanib is a potent inhibitor of VEGFR-1, 2 & 3 (IC(50) 0.21, 0.16 and 0.24nM respectively).
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors: F.A. Eskens, et al.; Clin. Cancer Res. 17, 7156 (2011)